Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
RNA viruses continue to remain a clear and present threat for potential pandemics due to their rapid evolution. To mitigate their impact, we urgently require antiviral agents that can inhibit multiple families of disease-causing viruses, such as arthropod-borne and respiratory pathogens. Potentiating host antiviral pathways can prevent or limit viral infections before escalating into a major outbreak. Therefore, it is critical to identify broad-spectrum antiviral agents. We have tested a small library of innate immune agonists targeting pathogen recognition receptors, including TLRs, STING, NOD, Dectin and cytosolic DNA or RNA sensors. We observed that TLR3, STING, TLR8 and Dectin-1 ligands inhibited arboviruses, Chikungunya virus (CHIKV), West Nile virus (WNV) and Zika virus, to varying degrees. Cyclic dinucleotide (CDN) STING agonists, such as cAIMP, diABZI, and 2',3'-cGAMP, and Dectin-1 agonist scleroglucan, demonstrated the most potent, broad-spectrum antiviral function. Comparative transcriptome analysis revealed that CHIKV-infected cells had larger number of differentially expressed genes than of WNV and ZIKV. Furthermore, gene expression analysis showed that cAIMP treatment rescued cells from CHIKV-induced dysregulation of cell repair, immune, and metabolic pathways. In addition, cAIMP provided protection against CHIKV in a CHIKV-arthritis mouse model. Cardioprotective effects of synthetic STING ligands against CHIKV, WNV, SARS-CoV-2 and enterovirus D68 (EV-D68) infections were demonstrated using human cardiomyocytes. Interestingly, the direct-acting antiviral drug remdesivir, a nucleoside analogue, was not effective against CHIKV and WNV, but exhibited potent antiviral effects against SARS-CoV-2, RSV (respiratory syncytial virus), and EV-D68. Our study identifies broad-spectrum antivirals effective against multiple families of pandemic potential RNA viruses, which can be rapidly deployed to prevent or mitigate future pandemics.
Identifiants
pubmed: 36711787
doi: 10.1101/2023.01.19.524824
pmc: PMC9882367
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI163216
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK132735
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY032149
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
J Clin Diagn Res. 2016 Dec;10(12):OD05-OD06
pubmed: 28208912
J Virol. 2014 Apr;88(8):4180-94
pubmed: 24478443
Nat Rev Immunol. 2015 Dec;15(12):760-70
pubmed: 26603901
Cases J. 2009 May 27;2:7147
pubmed: 19829922
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Infect Dis. 2017 Dec 16;216(suppl_10):S860-S867
pubmed: 29267917
Science. 2013 Sep 20;341(6152):1390-4
pubmed: 23989956
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
PLoS Pathog. 2015 Dec 08;11(12):e1005324
pubmed: 26646986
BMC Infect Dis. 2010 Oct 24;10:305
pubmed: 20969802
Nature. 2021 Sep;597(7874):109-113
pubmed: 34261127
Sci Immunol. 2021 May 18;6(59):
pubmed: 34010142
PLoS Negl Trop Dis. 2020 Jun 30;14(6):e0008135
pubmed: 32603322
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Science. 2005 Jul 22;309(5734):581-5
pubmed: 15961631
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Cell Rep. 2021 Apr 6;35(1):108940
pubmed: 33784499
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8967-71
pubmed: 1924357
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
PLoS One. 2007 Jun 13;2(6):e527
pubmed: 17565380
Microorganisms. 2022 Feb 03;10(2):
pubmed: 35208808
Genome Biol. 2014;15(12):550
pubmed: 25516281
JAMA. 2013 Jul 17;310(3):308-15
pubmed: 23860989
Virol Sin. 2017 Dec;32(6):520-532
pubmed: 29243070
Methods Mol Biol. 2014;1161:313-24
pubmed: 24899440
Adv Drug Deliv Rev. 2021 Dec;179:114020
pubmed: 34756942
Sci Rep. 2012;2:347
pubmed: 22470840
Lancet Infect Dis. 2018 Nov;18(11):e355-e361
pubmed: 29934112
JAMA Netw Open. 2020 Jul 1;3(7):e209303
pubmed: 32633763
F1000Res. 2017 Mar 29;6:390
pubmed: 28503297
Nat Rev Immunol. 2009 Jul;9(7):465-79
pubmed: 19521399
Leukemia. 2021 Apr;35(4):1100-1107
pubmed: 33262528
J Biol Chem. 2000 Dec 1;275(48):37853-9
pubmed: 10984480
Science. 2013 Aug 23;341(6148):903-6
pubmed: 23929945
Cell. 2011 Oct 14;147(2):436-46
pubmed: 22000020
EMBO J. 1999 Jun 1;18(11):3164-72
pubmed: 10357827
Front Immunol. 2018 Jun 14;9:1297
pubmed: 29963044
Int Immunol. 2018 Mar 8;30(2):43-51
pubmed: 29452403
Parasit Vectors. 2018 Jul 3;11(1):378
pubmed: 29970133
PLoS Negl Trop Dis. 2017 Jun 1;11(6):e0005654
pubmed: 28570693
Mol Cell. 2014 Apr 24;54(2):289-96
pubmed: 24766893
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Nat Immunol. 2013 Dec;14(12):1237-46
pubmed: 24185615
N Engl J Med. 2016 Dec 15;375(24):2321-2334
pubmed: 26943629
One Health. 2017 Jul 01;4:1-13
pubmed: 28785601
Nat Rev Immunol. 2006 Jan;6(1):33-43
pubmed: 16341139
Nature. 2014 Jan 30;505(7485):691-5
pubmed: 24284630
Signal Transduct Target Ther. 2021 Apr 30;6(1):170
pubmed: 33927185
Future Cardiol. 2021 Oct;17(7):1277-1291
pubmed: 33739142
Immunol Rev. 2009 Jan;227(1):75-86
pubmed: 19120477
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
PLoS Biol. 2022 Nov 8;20(11):e3001851
pubmed: 36346780
Oncoimmunology. 2020 Jun 16;9(1):1777624
pubmed: 32934881
Cell Rep Med. 2020 Jul 21;1(4):100052
pubmed: 32835305
Nature. 2009 Oct 8;461(7265):788-92
pubmed: 19776740
Front Microbiol. 2021 Jun 24;12:695173
pubmed: 34262552
Annu Rev Biochem. 2005;74:355-83
pubmed: 15952891
Nat Clin Pract Neurol. 2006 May;2(5):264-75
pubmed: 16932563
Philos Trans R Soc Lond B Biol Sci. 2015 Apr 5;370(1665):
pubmed: 25688020
Science. 2008 Apr 18;320(5874):379-81
pubmed: 18420935
J Infect Dis. 2021 Jun 15;223(12):2186-2196
pubmed: 33161431
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Am J Trop Med Hyg. 2014 Mar;90(3):410-417
pubmed: 24493674
Immunity. 2008 Aug 15;29(2):178-81
pubmed: 18701081
PLoS Pathog. 2020 Oct 15;16(10):e1008999
pubmed: 33057424
Front Microbiol. 2021 Oct 05;12:744164
pubmed: 34675908
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Nucleic Acids Res. 2021 Jan 8;49(D1):D394-D403
pubmed: 33290554
Cell Rep. 2021 Nov 9;37(6):109977
pubmed: 34758308
Front Microbiol. 2020 Jun 26;11:1297
pubmed: 32670231
Indian J Med Res. 2019 Jun;149(6):771-777
pubmed: 31496530
PLoS One. 2021 Mar 10;16(3):e0247314
pubmed: 33690657
J Virol. 2018 Feb 26;92(6):
pubmed: 29263267
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1848-57
pubmed: 22645348
Sci Rep. 2018 Jan 18;8(1):1045
pubmed: 29348627
Virulence. 2021 Dec;12(1):2060-2072
pubmed: 34410208